In a heart failure patient with elevated serum creatinine (eGFR ≥30 mL/min/1.73 m²), how should sacubitril/valsartan (angiotensin receptor‑neprilysin inhibitor) be initiated, titrated, and monitored?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Sacubitril/Valsartan in Heart Failure with Elevated Creatinine

Sacubitril/valsartan can and should be initiated in heart failure patients with elevated creatinine as long as eGFR ≥30 mL/min/1.73 m², using half the usual starting dose and careful monitoring of renal function, potassium, and blood pressure. 1

Initiation Strategy

Eligibility Criteria

Start sacubitril/valsartan if the patient meets these criteria:

  • eGFR ≥30 mL/min/1.73 m² (severe renal impairment is acceptable) 1
  • Serum potassium <5.2 mmol/L 2
  • Systolic blood pressure adequate (ideally >100 mmHg, though lower may be tolerated) 3
  • NYHA class II-IV heart failure with reduced ejection fraction 4, 5

Dosing in Renal Impairment

For eGFR ≥30 but <60 mL/min/1.73 m² (moderate renal impairment):

  • Start at 24/26 mg twice daily (half the usual starting dose) 1
  • Titrate every 2-4 weeks as tolerated
  • Target dose: 97/103 mg twice daily if tolerated

For eGFR <30 mL/min/1.73 m² (severe renal impairment):

  • Start at 24/26 mg twice daily (half the usual starting dose) 1
  • More cautious uptitration
  • Accept lower maintenance doses if higher doses not tolerated

For patients not previously on ACE inhibitor/ARB or on low doses:

  • Also start at 24/26 mg twice daily regardless of renal function 1

Monitoring Protocol

Initial Monitoring (Critical Period)

Check the following at 1-2 weeks after initiation and after each dose increase:

  • Serum creatinine and eGFR
  • Serum potassium
  • Blood pressure (supine and standing)
  • Volume status 6

Ongoing Monitoring

  • Monthly for first 3 months, then every 3-6 months once stable 5
  • More frequent monitoring if potassium >5.0 mmol/L or creatinine rising

Managing Renal Function Changes

Expected Changes (Do NOT Stop Therapy)

Creatinine increases up to 30% from baseline are acceptable and common 7, 8, 7

  • This represents hemodynamic adjustment, not true kidney injury
  • Continue therapy and monitor closely 9
  • Recent evidence shows sacubitril/valsartan actually slows eGFR decline long-term compared to enalapril 10, 11

Moderate eGFR Decline (>15%)

  • Do not discontinue therapy - this is often transient 9
  • eGFR typically partially recovers even with continued treatment
  • Treatment benefits are maintained regardless of initial eGFR decline 9
  • Continue monitoring every 1-2 weeks until stabilized

When to Reduce Dose or Stop

Reduce dose if:

  • Creatinine increases >50% from baseline 7
  • Symptomatic hypotension despite volume optimization
  • Potassium >5.5 mmol/L despite dietary modification

Stop therapy if:

  • eGFR drops below 30 mL/min/1.73 m² (though not an absolute contraindication per FDA) 1
  • Severe hyperkalemia (>6.0 mmol/L) unresponsive to management
  • Substantial renal function deterioration (>50% creatinine increase) 6

Key Clinical Considerations

Optimize Before Initiation

  1. Review diuretic dosing - reduce if patient is volume depleted 6
  2. Stop nephrotoxic agents - NSAIDs, COX-2 inhibitors 7
  3. Assess for reversible causes of renal dysfunction - infection, obstruction, hypotension 7
  4. Separate timing from other BP-lowering medications if symptomatic hypotension occurs 8

Concomitant Medications

  • Avoid potassium-sparing diuretics during initiation 6
  • If using spironolactone, monitor potassium very closely (every 5-7 days initially) 6
  • Do not combine with ACE inhibitors - requires 36-hour washout 1

Renoprotective Effects

Emerging evidence shows dose-dependent renoprotective effects 12:

  • Higher doses associated with better preservation of eGFR
  • Effect more pronounced in patients with proteinuria
  • Sacubitril/valsartan reduces risk of doubling serum creatinine by 23% vs. enalapril 10, 11

Common Pitfalls to Avoid

  1. Stopping therapy for mild creatinine increases (<30%) - this denies patients proven mortality benefit 9
  2. Failing to start due to "borderline" renal function - patients with eGFR 30-45 still benefit 10, 13
  3. Not reducing diuretics first - volume depletion exacerbates renal dysfunction 6
  4. Inadequate monitoring frequency - check labs 1-2 weeks after each change, not monthly 5
  5. Combining with triple RAAS blockade (ACEi + ARB + aldosterone antagonist) - excessive hyperkalemia risk 8

The evidence strongly supports that transient renal function changes should not prevent initiation or continuation of sacubitril/valsartan, as long-term renal and cardiovascular outcomes are superior to ACE inhibitors/ARBs. 9, 10, 11

References

Related Questions

In a patient with chronic kidney disease (creatinine 1.2 mg/dL) and heart failure with preserved ejection fraction (55 %), should I use sacubitril/valsartan (Entresto) or stick with an ACE inhibitor or ARB?
Is sacubitril/valsartan nephrotoxic?
Is it appropriate to prescribe Entresto (sacubitril/valsartan) to a patient with impaired renal function (eGFR 38 mL/min/1.73 m²)?
In a 75-year-old patient with serum potassium of 5.6 mmol/L and normal renal function, should the valsartan dose be reduced?
In an adult patient with estimated glomerular filtration rate ≥30 mL/min/1.73 m² and serum potassium <4.8 mmol/L, is valsartan more potent than losartan?
Why is intravenous milrinone administered?
What is testicular NASP (Nuclear Autoantigenic Sperm Protein)?
What nutritional therapy is recommended for patients with Graves disease?
In the SINGLE‑AF trial, for the no‑anticoagulant arm, how long was temporary anticoagulation permitted around cardioversion or other invasive cardiac procedures, and what happened if anticoagulation exceeded this period—were patients still considered part of the no‑anticoagulant group?
Is it appropriate to refer a patient with a superficial cheek abscess the size of a ping‑pong ball to general surgery or dermatology for incision and drainage?
Why were patients meeting the exclusion criteria excluded from the study, and was direct oral anticoagulant (DOAC) therapy indicated for them?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.